{"id":5629,"date":"2015-05-01T00:00:00","date_gmt":"2015-05-01T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/index.php\/2015\/05\/01\/pmn1404-article02\/"},"modified":"2019-02-18T20:38:47","modified_gmt":"2019-02-18T20:38:47","slug":"pmn1404-article02","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/pmn1404-article02\/","title":{"rendered":"PharmaPhobia & What to Do About It: Tom Stossel Attempts to Debunk the Conflict-of-Interest “Myth”"},"content":{"rendered":"

PharmaPhobia & What to Do About It Tom Stossel Attempts to Debunk the Conflict-of-Interest “Myth”
\"PharmaPhobiaThomas P. Stossel, M.D., visiting scholar at the American Enterprise Institute for Public Policy Research, recently published a new book titled PHARMAPHOBIA. The book is a call to action against the “Conflict of Interest Myth,” which Stossel claims is undermining American medical innovation. <\/p>\n

Stossel uses many combative terms to describe the focus of his critique. In his book and in a Pharma Marketing Talk interview (listen here<\/a>), Stossel repeatedly refers to the conflict-of-Interest “movement,” conflict-of-interest “mania,” and conflict-of-interest “instigators, enablers and enforcers,” which include physicians and even pharmaceutical executives according to Stossel. <\/p>\n

But will Stossel’s book, which ends with a section on “What is to be done,” turn the tide as he hopes it will? This article reviews some of Stossel’s main arguments. You be the judge. <\/p>\n

Topics (partial list)<\/b>:<\/p>\n